SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Sorrento Therapeutics Inc

04 May 2015 10:22 AM
30 Aug 2013 03:55 PM
29 Jan 2010 08:36 AM <--

Return to Sorrento Therapeutics Inc
 
Remember QBSW? Quikbyte did a reverse merger and is now:
"Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease."
Recent news starts like this:
"SAN DIEGO, Jan 11, 2010 /PRNewswire via COMTEX News Network/ --
Sorrento Therapeutics, Inc. (OTC Bulletin Board: SRNE) today announced an antibody discovery and development collaboration with The Scripps Research Institute, La Jolla, CA. Under the terms of the agreement, Sorrento Therapeutics obtains an exclusive, worldwide license to the Institute's novel technology, based on quorum sensing, for the prevention and treatment of Staphylococcus aureus ('Staph') infections, including Methicillin-resistant Staph. aureus (MRSA). ..."